LLY

1,085.09

+1.81%↑

JNJ

232.16

+1.19%↑

ABBV

213.26

+0.06%↑

UNH

383.22

+1.49%↑

AZN

187.9

+0.13%↑

LLY

1,085.09

+1.81%↑

JNJ

232.16

+1.19%↑

ABBV

213.26

+0.06%↑

UNH

383.22

+1.49%↑

AZN

187.9

+0.13%↑

LLY

1,085.09

+1.81%↑

JNJ

232.16

+1.19%↑

ABBV

213.26

+0.06%↑

UNH

383.22

+1.49%↑

AZN

187.9

+0.13%↑

LLY

1,085.09

+1.81%↑

JNJ

232.16

+1.19%↑

ABBV

213.26

+0.06%↑

UNH

383.22

+1.49%↑

AZN

187.9

+0.13%↑

LLY

1,085.09

+1.81%↑

JNJ

232.16

+1.19%↑

ABBV

213.26

+0.06%↑

UNH

383.22

+1.49%↑

AZN

187.9

+0.13%↑

Accueil・Liste d'Actions・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Ouvert

13.94 -0.43

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.84

Max

14.17

Chiffres clés
By Trading Economics
Revenu	-6.4M -20M
Ventes	-807K 71M
BPA	-0.13
Marge bénéficiaire	-28.24
Employés	624
EBITDA	-7.9M -14M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+45.32% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-95M 2.2B
Ouverture précédente	14.37
Clôture précédente	13.94

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 mai 2026, 16:52 UTC

Principaux Événements d'Actualité

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mai 2026, 23:57 UTC

Résultats

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mai 2026, 23:57 UTC

Résultats

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mai 2026, 21:54 UTC

Résultats

Webco Industries 3Q EPS $11.61 >WEBC

26 mai 2026, 21:54 UTC

Résultats

Webco Industries 3Q Sales $179.6M >WEBC

26 mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 mai 2026, 20:58 UTC

Acquisitions, Fusions, Rachats

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

26 mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

45.32% hausse

Prévisions sur 12 Mois

Moyen 20.17 USD 45.32%

Haut 22 USD

Bas 18 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.